Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reclast in postmenopausal osteoporosis (6-9 year extension)
NCT00718861Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2008
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of zoledronic acid in postmenopausal osteoporosis, sponsored by Novartis. Started May 2008; status: completed.
02
Drugs
zoledronic acid
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00718861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00718861.